Enlivex Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Enlivex Therapeutics
ENLV Stock  USD 1.12  0.00  0.00%   
Enlivex Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Enlivex Therapeutics' valuation are provided below:
Market Capitalization
263.5 M
Earnings Share
(0.54)
There are over one hundred nineteen available fundamental signals for Enlivex Therapeutics, which can be analyzed over time and compared to other ratios. All traders should should verify Enlivex Therapeutics' prevailing fundamental trends against the trends from 2010 to 2026 to make sure the company is sustainable. Market Cap is likely to drop to about 26.2 M in 2026. Enterprise Value is likely to drop to about 23.2 M in 2026

Enlivex Therapeutics Total Revenue

2.28 Million

Check Enlivex Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Enlivex Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 14.2 K, Total Revenue of 0.0 or Research Development of 7.5 M, as well as many indicators such as Price To Sales Ratio of 39.01, Dividend Yield of 0.0 or PTB Ratio of 1.11. Enlivex financial statements analysis is a perfect complement when working with Enlivex Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Enlivex Stock
Check out the analysis of Enlivex Therapeutics Correlation against competitors.
For more information on how to buy Enlivex Stock please use our How to Invest in Enlivex Therapeutics guide.

Enlivex Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets30.2 M24.9 M31 M
Pretty Stable
Other Current Liabilities2.4 M2.3 M2.1 M
Slightly volatile
Total Current Liabilities3.6 M3.4 M3.1 M
Slightly volatile
Total Stockholder Equity24.9 M21.2 M27.1 M
Very volatile
Accounts Payable1.1 M729.9 K796.5 K
Very volatile
Cash3.6 M3.8 M8.1 M
Pretty Stable
Short Term Investments13.8 M23.2 M18.5 M
Pretty Stable
Other Current Assets1.7 M1.2 M1.8 M
Very volatile
Total Liabilities5.4 M3.7 M3.9 M
Slightly volatile
Intangible Assets350.6 K369 K3.7 M
Slightly volatile
Common Stock3.2 M3.1 M1.1 M
Slightly volatile
Property Plant Equipment18 M17.1 M5.5 M
Slightly volatile
Long Term Debt3.4 M3.6 M4.1 M
Slightly volatile
Good Will19.9 M13.6 M16.2 M
Slightly volatile
Preferred Stock Total Equity10.2 M9.7 M8.2 M
Slightly volatile
Other Liabilities5.1 M4.9 M2.2 M
Slightly volatile
Cash And Short Term Investments23.2 M27.2 M19.1 M
Slightly volatile
Common Stock Total Equity2 M1.9 M818.5 K
Slightly volatile
Common Stock Shares Outstanding24.8 M23.6 M13.5 M
Pretty Stable
Liabilities And Stockholders Equity31.3 M31.8 M25.5 M
Slightly volatile
Other Stockholder Equity177.4 M168.9 M72 M
Slightly volatile
Total Current Assets28.5 M29.9 M23.3 M
Slightly volatile
Property Plant And Equipment Net1.3 M1.3 M2 M
Slightly volatile
Non Current Assets Total3 M1.9 M2.2 M
Slightly volatile
Property Plant And Equipment Gross4.4 M5.5 M3.2 M
Slightly volatile
Capital Surpluse32.3 M33.4 M38.2 M
Slightly volatile
Net Tangible Assets32.8 M65.4 M25.7 M
Slightly volatile
Net Invested Capital35 M27.1 M19.9 M
Slightly volatile
Net Working Capital32.2 M25.5 M18.5 M
Slightly volatile
Capital Stock2 M3.1 M1.5 M
Slightly volatile
Short and Long Term Debt Total583.4 K614.1 K568.3 K
Slightly volatile
Capital Lease Obligations579.7 K614.1 K321.3 K
Slightly volatile
Non Current Liabilities Other2.9 M4.8 M1.7 M
Slightly volatile
Short Term Debt442.2 K540.5 K264.8 K
Slightly volatile

Enlivex Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Research Development7.5 M11.6 M7.5 M
Slightly volatile
Cost Of Revenue466 K490.5 K3.8 M
Slightly volatile
Selling General Administrative7.8 M4.4 M5.6 M
Pretty Stable
Other Operating Expenses12.6 M17.9 M10.5 M
Slightly volatile
Total Operating Expenses13.4 M17.2 M11.2 M
Slightly volatile
Depreciation And Amortization318.2 K626.8 K260.6 K
Slightly volatile
Selling And Marketing Expenses7.4 M7 M3.7 M
Slightly volatile
Interest Income1.3 M1.2 M434.1 K
Slightly volatile
Reconciled Depreciation467.6 K626.8 K290.8 K
Slightly volatile

Enlivex Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Cash From Financing Activities14.5 M7.4 M14.9 M
Very volatile
Stock Based Compensation1.4 M2.4 M1.2 M
Slightly volatile
End Period Cash Flow4.1 M4.3 M7.4 M
Slightly volatile
Begin Period Cash Flow1.3 M1.4 M7.2 M
Slightly volatile
Sale Purchase Of Stock10.2 M7.5 M15.5 M
Slightly volatile
Depreciation344 K626.8 K260.6 K
Slightly volatile
Issuance Of Capital Stock11.2 M5.8 M9.2 M
Pretty Stable

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio39.0143.8847.8955
Slightly volatile
PTB Ratio1.111.1721.5 K
Slightly volatile
Book Value Per Share1.261.3214.0407
Slightly volatile
Stock Based Compensation To Revenue0.230.260.2885
Slightly volatile
Capex To Depreciation0.210.225.2335
Slightly volatile
PB Ratio1.111.1721.5 K
Slightly volatile
EV To Sales37.0841.7245.5352
Slightly volatile
Payables Turnover0.460.60.439
Slightly volatile
Sales General And Administrative To Revenue1.261.421.5534
Slightly volatile
Research And Ddevelopement To Revenue2.142.412.626
Slightly volatile
Capex To Revenue0.360.40.4396
Slightly volatile
Cash Per Share1.251.328.1794
Slightly volatile
Days Payables Outstanding59362511.1 K
Slightly volatile
Income Quality0.680.780.8105
Slightly volatile
Intangibles To Total Assets0.01860.0210.0229
Slightly volatile
Current Ratio11.887.879.6448
Very volatile
Tangible Book Value Per Share1.261.3214.0379
Slightly volatile
Shareholders Equity Per Share1.261.3214.0407
Slightly volatile
Debt To Equity0.02220.02040.018
Slightly volatile
Capex Per Share0.00550.00580.1224
Very volatile
Graham Net Net1.091.146.6285
Slightly volatile
Revenue Per Share0.140.160.1702
Slightly volatile
Interest Debt Per Share0.02280.0240.051
Slightly volatile
Debt To Assets0.01830.01740.0139
Slightly volatile
Price Book Value Ratio1.111.1721.5 K
Slightly volatile
Days Of Payables Outstanding59362511.1 K
Slightly volatile
Ebt Per Ebit0.80.870.9816
Pretty Stable
Company Equity Multiplier1.381.351.3598
Slightly volatile
Total Debt To Capitalization0.0210.01990.0174
Slightly volatile
Debt Equity Ratio0.02220.02040.018
Slightly volatile
Quick Ratio12.067.879.7823
Very volatile
Net Income Per E B T0.831.041.058
Slightly volatile
Cash Ratio0.951.05.2751
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.850.911.0297
Very volatile
Price To Book Ratio1.111.1721.5 K
Slightly volatile
Fixed Asset Turnover0.850.961.0453
Slightly volatile
Debt Ratio0.01830.01740.0139
Slightly volatile
Price Sales Ratio39.0143.8847.8955
Slightly volatile
Asset Turnover0.04510.05080.0554
Slightly volatile
Price Fair Value1.111.1721.5 K
Slightly volatile

Enlivex Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap26.2 M27.6 M1.7 B
Slightly volatile

Enlivex Fundamental Market Drivers

Enlivex Upcoming Events

29th of March 2024
Upcoming Quarterly Report
View
21st of June 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
29th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Enlivex Therapeutics Financial Statements

Enlivex Therapeutics investors use historical fundamental indicators, such as Enlivex Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Enlivex Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Cost Of Revenue490.5 K466 K
Stock Based Compensation To Revenue 0.26  0.23 
Sales General And Administrative To Revenue 1.42  1.26 
Research And Ddevelopement To Revenue 2.41  2.14 
Capex To Revenue 0.40  0.36 
Revenue Per Share 0.16  0.14 
Ebit Per Revenue(3.87)(4.06)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Enlivex Stock Analysis

When running Enlivex Therapeutics' price analysis, check to measure Enlivex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Enlivex Therapeutics is operating at the current time. Most of Enlivex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Enlivex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Enlivex Therapeutics' price. Additionally, you may evaluate how the addition of Enlivex Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY